Sammons HM, Malhotra J, Choonara I, Sitar DS, Matsui D, Rieder MJ. British and Canadian views on the ethics of paediatric clinical trials. European Journal of Clinical Pharmacology 2007;63(5):431–6.
Ethical concerns are often cited as reasons that clinical trials are not performed in children. Little is known about what researchers view as the ethically troublesome aspects of such trials. Therefore, in a pilot study, these authors used a questionnaire with sample clinical trial scenarios to examine the views of pediatricians and researchers in the United Kingdom and Canada. The questionnaire contained both questions and six clinical trial scenarios, each with an ethical dilemma. Respondents were asked whether they would approve such a trial and whether they thought that an ethics review board (ERB) would approve. Of 100 respondents (50 in each country), few had research ethics training (14% United Kingdom and 8% Canada). Most (80% and 88%) felt children could be harmed by participation in trials and half (47% and 59%) felt children should only participate if they receive direct benefit. Many (58% and 61%) disagreed with payments beyond travel expenses. In the trial scenarios, 34% of responders were willing to enter healthy children in a pharmacokinetics study of an antibiotic for cystic fibrosis and 22% believed that their ERBs would approve. Only one-third (33%) would enter children in a placebo-controlled analgesics trial. The authors concluded that pediatricians and researchers think that using healthy children and placebos in trials was cause for concern. Similar views were found in the two countries.
Seiler CM, Kellmeyer P, Kienle P, Buchler MW, Knaebel HP. Assessment of the ethical review process for nonpharmacological multicenter studies in Germany on the basis of a randomized surgical trial. Journal of Medical Ethics 2007;33(2):113–8.
These authors, anticipating problems in what they saw as a haphazard ethical review process (ERP) for their multicenter trial of a new suture material, responded by studying what occurred during their large study. They prospectively collected data at the Study Centre of the German Surgical Society on the duration, costs, and administrative effort of the ERP for their randomized controlled multicenter surgical study between November 2003 and May 2005. Study approval was handled by 18 ethics committees, including the ethics committee handling the primary approval, responsible overall for 32 clinical sites throughout Germany. Eight of the ethics committees were located at university medical schools and 10 at group practices. They measured the duration of the review process, calculated as the days between submission and receipt of final approval. They also calculated the costs in euros (€) and the administrative effort, the product of the total number of different types of documents and the mean number of copies required, with the primary approval process acting as the reference standard. They found that the duration of the ERP ranged from 1 to 176 (median 31) days. The median duration was 26 days at university medical schools compared with 34 days at group practices. The total cost was €2947. One of 8 ethics committees at universities (€250) and 8 of 10 at group practices charged a median fee of €162 (mean €270). The administrative effort for primary approval was calculated as 30 (documents × copies). Four ethics committees required a higher administrative effort for secondary approval (37, 39, 42, and 104). The authors conclude that the ERP for nonpharmacological multicenter trials in Germany needs improvement. The administrative process has to be standardized, including making the application forms and the number and content of the documents required identical, or at least similar. The fees need to be evaluated, because they vary considerably and are obviously too high for committees located at group practices. However, the duration of the ERP was, with some exceptions, excellent. A centralized ethics committee in Germany for multicenter trials would simplify the ERP for clinical investigators in and outside the country.
Schroter S, Plowman R, Hutchings A, Gonzalez A. Reporting ethics committee approval and patient consent by study design in five general medical journals. Journal of Medical Ethics 2006;32(12):718–23.
Most medical journals now require manuscripts to include descriptions of the ethical approval from an appropriate committee and how consent was obtained from participants when research involves human participants. These authors assessed the reporting of these protections for several study designs in general medical journals. These researchers reviewed a consecutive series of research papers published in the Annals of Internal Medicine, British Medical Journal, JAMA, Lancet, and The New England Journal of Medicine between February and May 2003 for the reporting of ethical approval and patient consent. Ethical approval, name of approving committee, type of consent, data source, and whether the study used data collected as part of a study reported elsewhere were recorded. Differences in failure to report approval and consent by study design, journal, and vulnerable study population were evaluated using multivariable logistic regression. They found that ethical approval and consent were not mentioned in 31% and 47% of manuscripts, respectively, and 88 (27%) papers failed to report both approval and consent. Failure to mention ethical approval or consent was significantly more likely in all study designs (except case-control and qualitative studies) than in randomized controlled trials (RCTs). Failure to mention approval was most common in the British Medical Journal and was significantly more likely than in The New England Journal of Medicine. Failure to mention consent was most common in the British Medical Journal and was significantly more likely than in all other journals. No significant differences in approval or consent were found when comparing studies of vulnerable and nonvulnerable participants. The reporting of ethical approval and consent in RCTs has improved, but journals are less good at reporting this information for other study designs. Journals should publish this information for all research on human participants.
Hilbrich L, Sleight P. Progress and problems for randomized clinical trials: From streptomycin to the era of megatrials. European Heart Journal 2006;27(18):2158–64.
These authors, from the Boehringer-Ingelheim Pharmaceutical Company, give the industry's perspective on the costs and regulations associated with randomized clinical trials (RCTs). They write that RCTs have been the primary contributors to evidence-based medicine. RCTs that assess serious outcomes in cardiovascular disease have grown, with “megatrials” becoming more common after a number of instances in which inadequately sized trials yielded wrong conclusions resulting from random error. Simple design and a heterogeneous patient population were early features, but multinational trials have increased in scientific, logistical, bureaucratic, regulatory, and legal complexity. These studies now exceed the financial means of academia or medical charities. Governments have left the bill with the pharmaceutical industry, encouraging a symbiosis with academics, who contribute medical and scientific expertise and access to patients. They claim that industry provides pharmacological, pharmaceutical, technical, and regulatory know-how, good clinical practice expertise, and legal assistance during the trial. Study supervision is then in the hands of an independent steering committee and associated subcommittees, until appropriate dissemination of results. Prospectively defined interaction with the sponsor facilitates unbiased design and conduct, but arrangements need careful implementation to avoid conflicts of interest. The patient is protected by a strong data safety monitoring board that is wholly independent. Although ethicists and regulators have challenged many of these claims of independence and patient safety, the authors accurately note that megatrials are under threat from overregulation, increasing costs, and difficulties in execution.
NIH State-of-the-Science Conference Statement on cesarean delivery on maternal request. NIH Consensus & State-of-the-Science Statements 2006;23(1):1–29.
How should physicians respond to patient requests for a cesarean delivery? To try to answer that question, the NIH held a “State-of-the-Science” Conference in 2006. They assembled an 18-member panel representing the fields of obstetrics and gynecology, preventive medicine, biometrics, family planning and reproductive physiology, nurse midwifery, anesthesiology, patient safety, epidemiology, pediatrics, perinatal medicine, urology, urogynecology, general nursing, inner city public health sciences, law, psychiatry, and health services research. It did not include members from either the Department of Health and Human Services or obvious advocates of a particular position on the topic. The panel heard data presented by 18 experts from pertinent fields and received a systematic review of the literature prepared by the RTI International–University of North Carolina Evidence-based Practice Center. Scientific evidence was given precedence over anecdotal experience. The panel drafted a statement based on the scientific evidence presented and on published scientific literature. After comments from the audience also listening to the testimony, they issued a revised statement that can be found at http://consensus.nih.gov. The statement is considered an independent report, not NIH or Federal Government policy. The panel concluded that the incidence of cesarean delivery without medical or obstetric indications is increasing in the United States, and that a component of this increase is cesarean delivery on maternal request. They found insufficient evidence to evaluate fully the benefits and risks of cesarean delivery on maternal request as compared to planned vaginal delivery, suggesting that more research is needed. Until that evidence becomes available, they felt that any decision to perform a cesarean delivery on maternal request should be carefully individualized and consistent with ethical principles. Given that the risks of placenta previa and accreta rise with each cesarean delivery, cesarean delivery on maternal request is not recommended for women desiring several children. Cesarean delivery on maternal request should not be performed prior to 39 weeks of gestation or without verification of lung maturity, because of the significant danger of neonatal respiratory complications.
